The Use of a Mitochondrial Enhancement Treatment in Bipolar Disorder
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this 15-week clinical trial is to test the hypothesis that treatment
with two proven mitochondrial enhancers, acetyl-L-carnitine (ALCAR) and α-lipoic acid (ALA),
has significantly greater efficacy than placebo as an augmentation treatment in bipolar
depressed patients who display an incomplete response to conventional treatments.